Hua Medicine (Shanghai) Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HUMDF research report →
Price Chart
About the company
Hua Medicine (Shanghai) Ltd. is a clinical-stage pharmaceutical firm specializing in treatments for diabetes, primarily targeting the Chinese market. Its flagship product is Dorzagliatin (also known as HMS5552), an oral medication currently being developed for managing Type 2 Diabetes (T2D).
- CEO
- Li Chen
- IPO
- 2021
- Employees
- 328
- HQ
- Shanghai, SH, CN
Get TickerSpark's AI analysis on HUMDF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $302.54M
- P/E
- -18.40
- Fwd P/E
- 5.01
- PEG
- 0.17
- P/S
- 2.90
- P/B
- 1.89
- EV/EBITDA
- -14.94
- Div Yield
- 0.00%
- Gross Margin
- 60.64%
- Op Margin
- -16.23%
- Net Margin
- -16.46%
- ROE
- -10.61%
- ROIC
- -7.77%
Latest fiscal year · YoY change
- Revenue
- $480.21M+87.7%
- Gross Profit
- $273.12M+119.0%
- Op Income
- $-141,143,190
- Net Income
- $1.08B+530.9%
- EPS
- $1.12+548.0%
- OCF Growth
- +87.5%
- FCF Growth
- +85.8%
- 52W High
- $0.50
- 52W Low
- $0.29
- 50D MA
- $0.31
- 200D MA
- $0.38
- Beta
- 0.77
- RSI (14)
- 54
- Avg Volume
- 230
No earnings-call transcripts are available for HUMDF yet.
- Free Float
- 60.4%
- Shares Outstanding
- 996.52M
- Float Shares
- 601.49M
Our HUMDF coverage
Recent articles, reports, and earnings notes.
No research on HUMDF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HUMDF report →Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.